Become a Member | Print Page | Contact Us | Report Abuse | Sign In
News & Press: News

ACCRU-ITOG-1504 Achieves Accrual Goal

Friday, May 15, 2020   (0 Comments)
Posted by: Judy Dallas
Share |


Congratulations to Principal Investigator:  Bryan Haugen  at  The University of Colorado Cancer Center and his team for achieving accrual goal of 60  ACCRU-ITOG-1504: Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive,  Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study. 

Connect With Us

International Thyroid Oncology Group

5166 Commercial Drive

Yorkville, New York 13495


Our mission
To catalyze a cure for the most challenging thyroid cancers through the collaborative efforts of our unique multidisciplinary team of leading physicians, scientists, and advocates to design, coordinate, and prioritize state-of-the-art clinical trials and correlative science.